Commercialization

Bright Lights, Bigger Screens - IDTechEx Explores Micro-LED Technology

Retrieved on: 
Monday, January 22, 2024

Micro-LEDs bring clearer displays and high brightness to large TV screens, while their lower power consumption makes them a more eco-friendly option.

Key Points: 
  • Micro-LEDs bring clearer displays and high brightness to large TV screens, while their lower power consumption makes them a more eco-friendly option.
  • Transparent screens could also be possible with micro-LEDs, as their spaced-out pixels allow for light to pass through, creating partial transparency.
  • With the development of micro-LEDs as a new and durable light source, displays are becoming bigger, brighter, and more flexible.
  • To find out more about the IDTechEx "Micro-LED Displays 2024-2034: Technology, Commercialization, Opportunity, Market and Players" report, including downloadable sample pages, please visit www.IDTechEx.com/MicroLED .

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Tuesday, January 16, 2024

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.
  • Charles River will officially launch the off-the-shelf Rep/Cap plasmid offering during Advanced Therapies Week , January 16-19, at the Miami Beach Convention Center.
  • Join Dr. Baghirzade in the Gene Therapy Manufacturing Track as part of the Regulatory Alignment for Gene Therapy Manufacturing session to learn how to:
    Ensure alignment with phase-appropriate plasmid DNA, AAV, and lentiviral vector (LVV) manufacturing best practices
    Matthew Hewitt, B.A.
  • Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and capacity expansions to simplify complex supply chains and meet the growing global demand for plasmid DNA, viral vector, and cell therapy services.

ADVANO Appoints J. Christopher York as Chief Executive Officer to Lead the Transition to an Application Oriented Enterprise Advancing Silicon-Carbon Composite Battery Materials

Retrieved on: 
Thursday, January 11, 2024

NEW ORLEANS, Jan. 11, 2024 /PRNewswire/ -- ADVANO, a silicon solutions provider, is accelerating the commercialization of its proprietary silicon anode "drop-in" technology, REALSi™. The transition to an application-oriented enterprise has been made possible with the new leadership of J. Christopher York and further advancements in ADVANO's silicon-carbon composite battery materials.

Key Points: 
  • The transition to an application-oriented enterprise has been made possible with the new leadership of J. Christopher York and further advancements in ADVANO's silicon-carbon composite battery materials.
  • ADVANO has engaged in significant product development efforts yielding a cost-effective, high-performance silicon-carbon composite material for energy storage.
  • Silicon is a critical material that will assume a leading role in the ongoing energy transition," said Christopher York.
  • Prior to joining ADVANO, Christopher held executive leadership positions for over two decades at distinguished companies, including NOVONIX and ELKEM.

Antheia Completes Successful Product Validation

Retrieved on: 
Monday, January 8, 2024

MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has completed a successful validation campaign for its first product, thebaine, consisting of three consecutive full-scale fermentation runs at 116,000L to demonstrate process efficacy and consistency. With the successful completion of this next manufacturing milestone, Antheia is rapidly advancing its commercial strategy to bring its Biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) to its leading global pharmaceutical customers.

Key Points: 
  • MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has completed a successful validation campaign for its first product, thebaine, consisting of three consecutive full-scale fermentation runs at 116,000L to demonstrate process efficacy and consistency.
  • "Achieving process validation with a novel bio-based process in just one year is phenomenal and speaks volumes to the technical capabilities of our R&D and operations teams," said Zack McGahey, COO of Antheia.
  • Completing a successful validation campaign in a short time frame is the result of Antheia's focused efforts to develop streamlined engineering solutions for its first product.
  • "Achieving this next milestone of a successful validation campaign comes on the heels of a hallmark year of transformative growth for Antheia and is a testament to our team's unwavering dedication to ending drug shortages," said Christina Smolke, PhD, CEO and co-founder of Antheia.

Kymanox Unveils Product Design, Development, and Commercialization Group Under Leadership of Chief Technology Officer

Retrieved on: 
Thursday, January 4, 2024

Newly appointed Chief Technology Officer, Nicholas (Nick) Ciccarelli, PE, who will lead the new group, emphasized the importance of optimal transitions between groups for faster speed to market.

Key Points: 
  • Newly appointed Chief Technology Officer, Nicholas (Nick) Ciccarelli, PE, who will lead the new group, emphasized the importance of optimal transitions between groups for faster speed to market.
  • Ciccarelli stated, "Our approach prioritizes the flow of information and ideas between teams, promoting efficiency at every stage.
  • By doing so, we're confident in our ability to accelerate product development timelines and get innovative solutions to market faster."
  • The newly formed Product Design, Development, and Commercialization group is structured to enhance collaboration and to leverage expertise and knowledge across the entirety of Kymanox’s 300 global employees.

Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24

Retrieved on: 
Thursday, January 4, 2024

Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.

Key Points: 
  • Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.
  • Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea.
  • Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024.
  • Additional indications of interest that are being actively pursued by Claris, supported by preclinical and clinical data, include limbal stem cell deficiency and pre-existing corneal scar.

Canadian Medical Isotope Ecosystem Announces Development Fund to Foster Innovation in the Canadian Isotope Industry

Retrieved on: 
Thursday, November 16, 2023

The Canadian Medical Isotope Ecosystem Development Fund (CMIEDF) will invest in Canadian projects that advance medical isotope supply or develop emerging technologies in radiotherapeutics and diagnostics.

Key Points: 
  • Vancouver, British Columbia and Ottawa, Ontario--(Newsfile Corp. - November 16, 2023) - On November 16, the Canadian Medical Isotope Ecosystem (CMIE) - an initiative co-led by TRIUMF Innovations and the Centre for Probe Development and Commercialization (CPDC) - held an industry information session to announce the launch of the Canadian Medical Isotope Ecosystem Development Fund (CMIEDF).
  • Through the new Development Fund, the CMIE will support industry collaboration and invest in promising Canadian projects that advance medical isotope supply or develop emerging technologies in radiotherapeutics and diagnostics.
  • With the creation of the Canadian Medical Isotope Ecosystem, we continue to develop a strong domestic production of pharmaceutical products that will contribute to make Canada a prized destination for the medical isotope industry, while creating highly skilled jobs across Canada," said Hon.
  • "This investment led to collaboration in the medical isotope sector with the creation of the Canadian Medical Isotope Ecosystem, and I have no doubt that the CMIEDF will lead to advances in medical isotopes to help Canada lead the world in medical isotopes."

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program

Retrieved on: 
Wednesday, November 29, 2023

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.

Key Points: 
  • Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.
  • Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi.
  • Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors.
  • +++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++

Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic

Retrieved on: 
Wednesday, December 20, 2023

The Company has raised a total of $157 million funding since its founding in 2020.

Key Points: 
  • The Company has raised a total of $157 million funding since its founding in 2020.
  • The Series B funding will be used to advance two investigational TYK2 candidates into the clinic next year.
  • Sudo is also developing a potential first-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.
  • “We are thankful for the support of our premier life science investors, which will allow us to advance our two development candidates into the clinic,” said Scott Byrd, CEO, Sudo Biosciences.

Alternative Protein Development and Commercialization - Stakeholder Use Cases on Overcoming Challenges Related to Alternative Proteins, Featuring Bell Food Group, Unilever and Simple Eggless

Retrieved on: 
Tuesday, December 19, 2023

DUBLIN, Dec. 19, 2023 /PRNewswire/ -- The "Technological Advances that Overcome Challenges to Alternative Protein Development and Commercialization" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 19, 2023 /PRNewswire/ -- The "Technological Advances that Overcome Challenges to Alternative Protein Development and Commercialization" report has been added to ResearchAndMarkets.com's offering.
  • The growing global demand for sustainable and ethical food sources has led to significant advancements in alternative proteins.
  • From plant-based proteins to cellular agriculture and novel fermentation techniques, researchers and industry pioneers are leveraging biotechnology, data analytics, and process optimization to enhance the efficiency and scalability of alternative protein production.
  • This analytics identifies the potential challenges in current alternative protein production and adoption and how technologies are advancing to handle some of these issues more from a processing and formulation standpoint.